SCYNEXIS raises $40M in dilutive private placement, issues 43.5M shares plus 43.5M warrants

Filed March 31, 2026 · Period ending March 30, 2026 · ~1 min read

Key Changes

• high

  Company sold 43.5M shares/pre-funded warrants at $0.92 each for ~$40M gross proceeds, representing significant dilution to existing shareholders. CEO participated in the offering.

  Item 1.01 verify on EDGAR →
• high

  Issued warrants to buy 43.5M additional shares at $1.20 (30% above offering price), exercisable only after shareholder approval and expiring 30 days after Phase 2 kidney disease trial data or 5 years.

  Item 1.01 verify on EDGAR →
• high

  Cash runway extended into mid-2029 with new proceeds (excluding warrant exercises), reducing near-term financing risk but at cost of substantial shareholder dilution.

  Item 8.01 verify on EDGAR →